<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02053805</url>
  </required_header>
  <id_info>
    <org_study_id>0582_13_RMC</org_study_id>
    <nct_id>NCT02053805</nct_id>
  </id_info>
  <brief_title>Prostate Cancer Screening Among Men With High Risk Genetic Predisposition</brief_title>
  <official_title>Personalized Prostate Cancer Screening Among Men With High Risk Genetic Predisposition- a Prospective Cohort Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rabin Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rabin Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This will be a prospective diagnostic trial of screening for prostate cancer among men with
      genetic predisposition.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be a prospective diagnostic trial of screening for prostate cancer among men with
      genetic predisposition. The target population is males (40-70 year old) carrying a BRCA1
      and/or BRCA2 germ line mutation. They will be identified via our Genetic counseling unit. All
      men after signing an informed consent will undergo the following tests: PSA, free to total
      PSA, MRI of prostate and prostate biopsy. The primary endpoint will be to estimate the
      prevalence, stage and grade of prostate cancer in this population. Additionally, the study
      aims to estimate the impact of these germ line mutations on benign prostatic hyperplasia.
      Furthermore, this study aims to create a bio-bank of tissue, urine and serum of this unique
      cohort for future investigations. Finally, this study will identify an inception cohort for
      future interventional studies of primary and secondary prevention.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Prevalence, stage and pathology of screen-detected prostate cancer in BRCA1/BRCA2 founder mutation carriers and Lynch mutation carriers</measure>
    <time_frame>within 2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Accuracy of different screening tests (PSA, free to total PSA, prostate MRI) in detecting prostate cancer among men with genetic predispositions.</measure>
    <time_frame>within 2 years</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Accuracy of different screening tests (PSA, free to total PSA, prostate MRI) in detecting clinically significant prostate cancer among men with genetic predispositions.</measure>
    <time_frame>within 2 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Cost effectiveness of different screening tests (PSA, free to total PSA, prostate MRI) in detecting prostate cancer and clinically significant prostate cancer among men with genetic predispositions.</measure>
    <time_frame>within 2 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Impact of genetic mutations (BRCA, Lynch) on lower urinary tract symptoms (IPSS, flow and post void urine residual) and BPH ( benign prostatic hyperplasia).</measure>
    <time_frame>within 2 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Genomic and biological profiles in samples from BRCA and Lynch mutation carriers and characterize changes related to prostate cancer.</measure>
    <time_frame>within 2 years</time_frame>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>BRCA1 Syndrome</condition>
  <condition>BRCA2 Syndrome</condition>
  <condition>Lynch Syndrome</condition>
  <arm_group>
    <arm_group_label>screening tests</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>The screening will include: DRE, PSA , a multiparametric prostate MRI and a trans-rectal ultra-sound guided prostate biopsy/ MRI-US fusion , IPSS questionnaire, trans-rectal US assessment of prostate size, urine flow and residual.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>PSA</intervention_name>
    <description>PSA. Serum &amp; plasma will be stored for future investigations</description>
    <arm_group_label>screening tests</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>IPSS questionnaire</intervention_name>
    <description>the validated International Prostate Symptom Score</description>
    <arm_group_label>screening tests</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>DRE (Digital Rectal Examination )</intervention_name>
    <description>physical examination for the prostate gland</description>
    <arm_group_label>screening tests</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>urine flow and residual</intervention_name>
    <description>The post void residual will be recorded by using ultrasound. Creatinine level will be checked.</description>
    <arm_group_label>screening tests</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>a multiparametric prostate MRI</intervention_name>
    <description>The MRI will be reported on a 5 point Likert Scale</description>
    <arm_group_label>screening tests</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>trans-rectal ultra-sound guided prostate biopsy</intervention_name>
    <description>12 core Trans-rectal prostatic biopsy for diagnostic purposes</description>
    <arm_group_label>screening tests</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male carrier of mutation in BRCA 1\2 or germ-line mutations in the MMR genes (MLH1,
             MSH2 , MSH6 or PMS2).

          -  WHO performance status 0-2 (Appendix 2)

          -  Absence of any psychological, familial, sociological or geographical situation
             potentially hampering compliance with the study protocol and follow-up schedule.

          -  Individuals that cannot undergo the MRI exam due to high creatinine level or
             claustrophobic will be disc loud from the MRI part.

          -  Informed written consent must be sought according to ICH/EU GCP, before subject
             registration.

        Exclusion Criteria:

          -  Previous cancer with a terminal prognosis of less than five years.

          -  Previous prostate cancer
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Margel, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rabn Medical Center, Beilinson Campus</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rachel Ozalvo, B.sc, MBA</last_name>
    <phone>+972(0)3-9376553</phone>
    <email>racheloz@clalit.org.il</email>
  </overall_contact>
  <location>
    <facility>
      <name>Rabin Medical Center - Beilinson Hospital</name>
      <address>
        <city>Petah Tikva</city>
        <zip>4941492</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rachel Ozalvo, B.sc MBA</last_name>
      <phone>972-3-9376553</phone>
      <email>racheloz@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>David Margel, MD, PhD</last_name>
      <phone>972-3-9376553</phone>
      <email>sdmargel@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>David Margel, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eli Rosenbaum, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Victoria Neiman, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rinat Yerushalmi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ofer Benjaminov, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Inbal Kedar</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ofer Yossepowitch, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Daniel Kedar, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jack Baniel, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Zohar Levi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Baruch Brenner, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Irit Ben Aharon, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rabin Medical Center, Beilinson Hospital</name>
      <address>
        <city>Petah Tikva</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Margel, MD PhD</last_name>
      <phone>+972(0)39378089</phone>
    </contact>
    <investigator>
      <last_name>David Margel, MD Phd</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 30, 2014</study_first_submitted>
  <study_first_submitted_qc>February 2, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 4, 2014</study_first_posted>
  <last_update_submitted>October 15, 2017</last_update_submitted>
  <last_update_submitted_qc>October 15, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>prostate cancer</keyword>
  <keyword>BRCA1 Syndrome</keyword>
  <keyword>BRCA germ-line mutation</keyword>
  <keyword>Lynch syndrome</keyword>
  <keyword>BRCA2 Syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Disease Susceptibility</mesh_term>
    <mesh_term>Colorectal Neoplasms, Hereditary Nonpolyposis</mesh_term>
    <mesh_term>Genetic Predisposition to Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

